Kidswell Bio Corporation(4584) News

Confirming Alignment on the Cerebral Palsy Clinical Trial Plan at the Pre-IND Meeting with U.S. FDA (SQ-SHED's Overseas Development)

Interim Results of SHED Clinical Study for Children with Cerebral Palsy Disclosed by Nagoya University

Summary of Consolidated Financial Results for 2Q of the Fiscal Year Ended March 31, 2026

Financial Results for FY2025 Q2

Kidswell Bio, Operating Loss Forecast for the Fiscal Year Revised Upward to 0.30-0.60 Billion Yen

"Treg" with "SHED" Toward the Development of an Innovative Immune Cell Therapy -Joint Research Agreement with Tokyo University of Science-

Toward a New Infertility Treatment Utilizing SHED - Commencement of Joint Research with LYMPHOGENiX (UK) -

SHED Clinical Study for Cerebral Palsy Data Safety Monitoring Board Confirms "No Safety Concerns"

Execution of Agreements regarding the Joint Development of Biosimilars for Specified Products

Agreement in Principle to Establish a Joint Venture Alliance for the Development of Domestic Manufacturing Facility for Biosimilars

Publication of Research Paper on the Application of SHED in the Treatment of Peripheral Nerve Injuries

Kidswell Bio, Apr-Jun (1Q) Ordinary Profit Turns to Profit

Financial Results for FY2025 Q1

Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2026

Kidswell Bio, Last Fiscal Year's Operating Profit Unexpectedly Turns Profitable, The Current Fiscal Year's Operating Profit Turns to Loss

Kidswell Bio, The Current Fiscal Year Ordinary Profit Loss to Narrow

Kidswell Bio, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Increases by 64%

Kidswell Bio Corporation, The Current Fiscal Year's Net Income to Narrow